Human papillomavirus (HPV) vaccination and oropharyngeal HPV in ethnically diverse, sexually active adolescents: community-based cross-sectional study. by Kerry-Barnard, S et al.
1Kerry- Barnard S, et al. Sex Transm Infect 2020;0:1–3. doi:10.1136/sextrans-2020-054428
Epidemiology
SHORT REPORT
Human papillomavirus (HPV) vaccination and 
oropharyngeal HPV in ethnically diverse, sexually 
active adolescents: community- based cross- 
sectional study
Sarah Kerry- Barnard,1 Simon Beddows,2 Fiona Reid,3 Nicholas Beckley- Hoelscher,3 
Kate Soldan,2 Kavita Panwar,2 Cangul Seran,2 Charlotte Fleming,4 Agata Lesniewska,1 
Tim Planche,5 Jonathan Williamson,1 Phillip Hay,6 Pippa Oakeshott  1
To cite: Kerry- Barnard S, 
Beddows S, Reid F, et al. 
Sex Transm Infect Epub ahead 
of print: [please include Day 
Month Year]. doi:10.1136/
sextrans-2020-054428
1Population Health Research 
Institute, St George’s University 
of London, London, UK
2National Infection Service, 
Public Health England, London, 
UK
3School of Population Health 
and Environmental Sciences, 
King’s College London, London, 
UK
4Clinical Trials Unit, London 
School of Hygiene and 
Tropical Medicine, Faculty of 
Epidemiology and Public Health, 
London, UK
5Infection and Immunity, St 
George’s University of London, 
London, UK
6Burrell Street Sexual Health 
Clinic, Guys and St Thomas’ NHS 
Foundation Trust, London, UK
Correspondence to
Professor Pippa Oakeshott, 
Population Health Research 
Institute, University of London 
Saint George’s, London SW17 
ORE, UK;  oakeshot@ sgul. ac. uk
Received 3 January 2020
Revised 7 July 2020
Accepted 26 July 2020
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objectives Oropharyngeal squamous cell carcinoma 
is the most common human papillomavirus (HPV)- 
associated cancer in the UK, but little is known about 
the prevalence of oropharyngeal HPV in sexually active 
teenagers. We investigated reported HPV vaccination 
coverage (in females) and prevalence of oropharyngeal 
HPV in sexually active students attending six technical 
colleges in London, UK.
Methods In 2017, we obtained mouthwash samples 
and questionnaires from male and female students 
taking part in the ’Test n Treat’ chlamydia screening trial. 
Samples were subjected to HPV genotyping.
Results Of 232 participants approached, 202 (87%) 
provided a mouthwash sample and questionnaire. 
Participants’ median age was 17 years and 47% were 
male. Most (73%) were from black and minority ethnic 
groups, 64% gave a history of oral sex, 52% reported 
having a new sexual partner in the past 6 months, 33% 
smoked cigarettes, 5.9% had concurrent genitourinary 
Chlamydia trachomatis infection and 1.5% Neisseria 
gonorrhoeae and 5.0% were gay or bisexual. Only 47% 
(50/107) of females reported being vaccinated against 
HPV 16/18, of whom 74% had received ≥2 injections. 
HPV genotyping showed three mouthwash samples 
(1.5%, 95% CI 0.3% to 4.3%) were positive for possible 
high- risk human papillomavirus (HR- HPV), one (0.5%, 
0.0% to 2.7%) for low- risk HPV 6/11, but none (0.0%, 
0.0% to 1.8%) for HR- HPV. Four samples (2.0%, 0.5% 
to 5.0%) were positive for HPV16 using a HPV16 type- 
specific quantitative PCR, but these were at a very low 
copy number and considered essentially negative.
Conclusions Despite the high prevalence of oral sex 
and genitourinary chlamydia and low prevalence of HPV 
vaccination, the prevalence of oropharyngeal HR- HPV in 
these adolescents was negligible.
INTRODUCTION
In 2016, oropharyngeal squamous cell carcinoma in 
men overtook cervical cancer as the most common 
human papillomavirus (HPV)- associated cancer in 
the UK.1 This increase is largely due to carcino-
genic/high- risk human papillomavirus (HR- HPV) 
transmitted by unprotected oral sex. Although 
70% of 16–24 year olds in England report having 
oral sex,2 many are unaware that this can lead to 
sexually transmitted infections (STIs) including 
HR- HPV in the throat.3
In 2008, a school- based HPV16/18 vaccination 
programme to prevent cervical cancer was estab-
lished in England for 12–13 year old girls, with 
‘catch- up’ vaccination for those aged 14–18. HPV 
vaccination may also protect against oral HR- HPV.4 
However, the natural history of oropharyngeal 
HPV is not fully understood5 6 and there is a dearth 
of UK data from sexually active teenagers, espe-
cially those from black and ethnic minority groups. 
Such groups may be hard to reach and have high 
prevalences of STIs.7 8
In 2017–2018, we explored the coverage of 
reported HPV vaccination (in females), feasibility 
of obtaining mouth wash samples and prevalence of 
oropharyngeal HPV in ethnically diverse, sexually 
active male and female adolescents taking part in 
the ‘Test n Treat’ chlamydia screening study.7
METHODS
The Test n Treat study assessed the feasibility of 
providing on- site same day testing and treatment 
for chlamydia to sexually active London further 
education/technical college students aged 16–24.7 
At 7 months follow- up in college, participants 
completed a sexual health questionnaire (including 
history of HPV vaccination for females only) and 
provided self- taken genitourinary samples for chla-
mydia/gonorrhoea testing (Cepheid GeneXpert). 
Participants were also given an additional informa-
tion sheet and asked to sign a consent form if they 
were willing to provide a mouthwash sample for 
HPV/chlamydia/gonorrhoea testing.3
Mouthwash sample collection
Under the supervision of a research nurse, each 
participant gargled 10 mL of saline solution for 
30 s and spat it back into the collection container. 
The container was then shaken to ensure an even 
distribution of cells and 2 mL was transferred to a 
Cobas PCR Media tube (for chlamydia/gonorrhoea 
testing using the urine protocol for the Roche 4800 
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machine). Samples were kept in a cool bag during the field visit 
and transferred to a −80 °C freezer the same day.
Sample processing
Samples were centrifuged (3200 × g, 15 min, 4 °C), washed with 
5 mL phosphate- buffered saline (PBS; 3200 × g, 15 min, 4 °C) 
and resuspended in 1 mL PBS before nucleic acid extraction.
HPV testing
Genotyping for HR- HPV (HPV16/18/31/33/35/39/45/51/52/56/
58/59/68), possible HR- HPV (HPV26/53/66/70/73/82) and low 
risk (LR)- HPV (HPV 6/11) was conducted using a universal probe 
(96% sensitivity, 71% specificity) and 21 type- specific probes 
against the indicated genotypes, as previously described,9 10 and 
we report the following categorical readouts: HR- HPV, possible 
HR- HPV and LR- HPV. Assessment of sample volume (n=90) 
and cellular content using a quantitative human glyceraldehyde 
3- phosphate dehydrogenase (GAPDH) PCR (n=30) confirmed 
adequate sample quality.3 9 10 An HPV16 quantitative PCR was 
used as an additional test to detect HPV16.10 We used descrip-
tive statistics to summarise HPV types.
RESULTS
Of 232 Test n Treat participants attending follow- up, 202 (87%) 
provided a mouthwash sample. Participants’ median age was 17 
years, 47% were male and 64% gave a history of oral sex. Six 
per cent had concurrent genitourinary chlamydia infection and 
1.5% had gonorrhoea (table 1). They described their ethnicity 
as black 53% (105/199), white 27% (54/199) and other ethnic 
groups 20% (40/199).
HPV vaccine coverage
Less than half (47%, 50/107) of the female participants reported 
being vaccinated against HPV (and 5% (5/107) did not know 
whether they had been vaccinated). All were in age groups 
eligible for the main vaccination rollout at age 12–13 (n=107) 
or the ‘catch- up’ vaccination (n=1). A higher proportion of 
white students reported receiving the vaccination than black 
and ethnic minority students, 62% (16/26) vs 41% (33/80). Half 
(50%, 25/50) of all vaccinated students received three injections, 
24% (12/50) received two and 26% (13/50) were not sure how 
many injections they had received. No one reported only one 
injection. Of females who said they had not been vaccinated, 
60% (31/52) reported attending a sexual health clinic in the 
previous 6 months.
HPV genotyping
Of the 202 samples, three (1.5%, 95% CI 0.3% to 4.3%) were 
positive for possible HR- HPV, one of which (0.5%, 0.0% to 
2.7%) was also positive for LR- HPV6/11. No samples (0.0%, 
0.0% to 1.8%) were positive for HR- HPV. Four of the 202 
samples (2.0%, 0.5% to 5.0%) were positive for HPV16 using a 
HPV16 type- specific quantitative PCR, but this was at a very low 
level (equivalent to 1 copy per 30 000 cells) and was considered 
essentially negative.
Additional STI testing
Of 202 valid mouthwash samples tested for Chlamydia tracho-
matis and Neisseria gonorrhoeae, one (0.5%, 0.0%–2.7%) 
was positive for chlamydia (in a female with no genitourinary 
chlamydia).
DISCUSSION
Principal findings
Despite high prevalences of oral sex and genitourinary chla-
mydia/gonorrhoea and low self- reported uptake of HPV vaccina-
tion (especially in those from black and ethnic minority groups), 
we found no HR- HPV.
Strengths and weaknesses
This is the first UK community- based study of oral HPV in ethni-
cally diverse, sexually active adolescents. Many previous studies 
were of mainly white individuals or those attending healthcare 
facilities.6 9 11 In contrast to an oral HPV prevalence study in 
which the median age was 31 years,11 89% of our participants 
were teenagers7 making this the largest UK study of oropha-
ryngeal HPV in this age group. The UK setting with its school 
vaccination programme and NHS is also different from North 
and South America.11 In addition 73% of our participants were 
from black and minority ethnic groups, often from less affluent 
backgrounds,7 and a third were smokers (which may increase the 
risk of oral HPV).5 Such groups may lack knowledge of STIs3 7 
and have relatively low uptake of preventive health measures.8 
Finally, the high response rate to providing mouthwash samples3 
and success in keeping them cool before freezing shows such 
studies are feasible in the community.
The main limitation of this observational study is a lack of 
power due to the relatively small sample size which was deter-
mined to give adequate precision in the feasibility outcomes 
of the Test n Treat study.7 However, the number of under 25s 
is similar to another UK study12 and much greater than in the 
Hopscotch study which struggled to recruit young people.6 
Although there are no data on oral HPV prevalence in a similar 
but prevaccine UK cohort, our previous community- based study 
of 939 unvaccinated female students aged <20 found high 
prevalences (19.7%) of HR- HPV in vaginal samples.8 We only 
included participants of the Test n Treat study, and students who 
had not had penetrative sex were excluded. However, other 
studies have sampled similarly restricted populations such as 
sexual health service attendees, dental patients or men who have 
sex with men (MSM).4 6 9 We relied on self- report of vaccination 
Table 1 Characteristics of 202 ethnically diverse, sexually active Test 
n Treat participants who provided mouthwash samples for HPV testing
Characteristic
All participants 
(n=202)
Females 
(n=108)
Median age in years (IQR) 17 (16–18) 17 (16–18)
Black or minority ethnic group, n/N (%) 145/199 (72.9%) 80/106 (75.5%)
New partner in the past 6 months, n/N (%) 104/201 (51.7%) 49/107 (45.8%)
MSM/WSW, n/N (%) 10/201 (5.0%) 5/107 (4.7%)
Smokes cigarettes, n/N (%) 59/179 (33.0%) 28/93 (30.1%)
Drunk due to alcohol in the past month, n/N (%) 92/200 (46.0%) 44/107 (41.1%)
Oral sex ever, n/N (%) 120/187 (64.2%) 64/101 (63.4%)
Reported HPV vaccination if female, n/N (%) 50/107 (46.7%)
HR- HPV*, n/N (%) 0/202 (0.0%) 0/108 (0.0%)
LR- HPV 6/11, n/N (%) 1/202 (0.5%) 1/108 (0.9%)
Possible HR- HPV†, n/N (%) 3/202 (1.5%) 2/108 (1.8%)
Genitourinary chlamydia, n/N (%) 12/202 (5.9%) 9/108 (8.3%)
Genitourinary gonorrhoea, n/N (%) 3/202 (1.5%) 3/108 (2.8%)
Oral chlamydia, n/N (%) 1/202 (0.5%) 1/108 (0.9%)
Oral gonorrhoea, n/N (%) 0/202 (0.0%) 0/108 (0.0%)
Participants with missing data were excluded from the denominator totals
*HR- HPV includes HPV16/18/31/33/35/39/45/51/52/56/58/59/68.
†Possible HR- HPV includes HPV26/53/66/70/73/82.
HPV, human papillomavirus; HR- HPV, high- risk human papillomavirus; MSM, men who have 
sex with men; WSW, women who have sex with women.;
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status and sexual behaviour which can be inaccurate. However, 
the proportion reporting oral sex (64%) was similar to young 
people aged 16–24 in a British population- based study.2 In addi-
tion, all immunised females who responded to the question, 
reported receiving two or more HPV vaccinations lending cred-
ibility to their responses. In line with this, a recent UK study 
found that 86% of participants’ reports of HPV vaccination were 
confirmed from medical records.6 Finally, our findings may not 
be applicable to different populations such as clinic or hospital 
attendees and those from less developed countries.
Comparison with other studies
Our prevalences of HR- HPV and HPV16 were lower than 
the 2.3% and 0.8%, respectively, in under 25s in a systematic 
review5 of 28 544 healthy individuals worldwide, but similar 
to those in an unvaccinated low risk male cohort from USA, 
Mexico and Brazil11 and to recent UK reports.6 12 Hearnden and 
colleagues found only 1% (2/223) of 18–25 year olds from Shef-
field, England had oral HR- HPV,12 and as in our study none had 
HPV16. Both infections were in heterosexual males aged ≥21 
which is older than nearly all of our participants. Higher preva-
lences are found in MSM.5 9
Less than half the female participants reported HPV vacci-
nation, which is lower than the average 70% coverage across 
London. However, half our sample were of black ethnicity, a 
group who are less likely to be vaccinated despite being at 
greater risk of both HR- HPV and cervical cancer.8 Such inequal-
ities highlight the need for public health measures to address 
barriers to HPV vaccination. One way to boost coverage might 
be opportunistic HPV vaccination of clinic attendees since 60% 
of unvaccinated females in our study had recently visited a sexual 
health clinic.
Implications
These findings could inform health policy. Although these 
adolescents had high prevalences of genitourinary STIs and 
engaged in oral sex, we found no cases of oral HPV16 infection. 
Despite the caveats of a small observational study, our findings 
are interesting and may partly reflect the impact of HPV vacci-
nation on herd immunity.4 However, the low coverage of HPV 
vaccination, particularly in females from ethnic minority groups, 
is concerning as there is no treatment for HPV, and the key to 
prevention of HPV- associated oropharyngeal cancer is prophy-
lactic HPV vaccination.
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